{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-017082","form_type":"8-K","ticker":"EVFM","cik":"0001618835","company_name":"Evofem Biosciences, Inc.","filed_at":"2026-04-16T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.600211+00:00","generated_at":"2026-05-15T05:47:02.030598+00:00","sec_items":["1.01","9.01"],"event_type":"debt","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Evofem Biosciences extends maturity of Adjuvant convertible notes by six months","bullets":["Fourth Amendment to Securities Purchase Agreement dated April 10, 2026 with Adjuvant Global Health Technology Fund.","Notes now due six months after April 10, 2026 (approx. Oct 10, 2026), or upon change of control or acceleration.","No prepayment of notes allowed before that six-month date without Adjuvant's prior written consent.","Amendment updates maturity definition in Section 3.1 of the Purchase Agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-017082","json":"https://secwatch.observer/filing/0001493152-26-017082.json","markdown":"https://secwatch.observer/filing/0001493152-26-017082.md","text":"https://secwatch.observer/filing/0001493152-26-017082.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T05:47:02.030598+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d18db34d19d2c442097325b0506fcc2261255db3","claim":"Evofem Biosciences, Inc. amended Fourth Amendment with Adjuvant Global Health Technology Fund, L.P. and Adjuvant Global Health Technology Fund DE, L.P. (together, Adjuvant) (effective 2026-04-10).","evidence_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","confidence":0.9}],"comparable_filings":[{"accession":"0001193125-26-252668","ticker":"BTU","company_name":"PEABODY ENERGY CORP","filed_at":"2026-06-02T14:17:48+00:00","headline":"Peabody prices $250M convertible notes due 2031, repurchases $241.2M of 2028 notes","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-252668","json":"https://secwatch.observer/filing/0001193125-26-252668.json","markdown":"https://secwatch.observer/filing/0001193125-26-252668.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1064728/000119312526252668/0001193125-26-252668-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1064728/000119312526252668/d112966d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"Convertible Notes and the Indenture On May 28, 2026, Peabody Energy Corporation (the “Company” or “Peabody”) priced its private offering of $225 million in aggregate principal amount of 0.50% Convertible Senior Notes due 2031 (the “Initial Notes”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1064728/000119312526252668/0001193125-26-252668-index.htm"}},{"accession":"0001882781-26-000041","ticker":"CBLO","company_name":"C2 Blockchain, Inc.","filed_at":"2026-06-02T14:08:44+00:00","headline":"C2 Blockchain raises $130K and up to $1.2M via convertible notes with heavy dilution","event_type":"debt","sec_items":["1.01","2.03","3.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001882781-26-000041","json":"https://secwatch.observer/filing/0001882781-26-000041.json","markdown":"https://secwatch.observer/filing/0001882781-26-000041.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1882781/000188278126000041/0001882781-26-000041-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1882781/000188278126000041/form8k6226o.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On May 28, 2026, the Company entered into a Securities Purchase Agreement with Leonite Fund I, LP (“Leonite”), pursuant to which the Company issued and sold a Senior Secured Convertible Promissory Note having an aggregate principal amount of up to $1,200,000 (the “Leonite Note”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1882781/000188278126000041/0001882781-26-000041-index.htm"}},{"accession":"0001993004-26-000044","ticker":"NWE","company_name":"NorthWestern Energy Group, Inc.","filed_at":"2026-06-02T11:22:44+00:00","headline":"NorthWestern Energy subsidiary enters $225M secured term loan, repays revolver","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001993004-26-000044","json":"https://secwatch.observer/filing/0001993004-26-000044.json","markdown":"https://secwatch.observer/filing/0001993004-26-000044.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1993004/000199300426000044/0001993004-26-000044-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1993004/000199300426000044/nwe-20260527.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On May 27, 2026, NorthWestern Corporation (\" NW Corp \"), a wholly owned subsidiary of NorthWestern Energy Group, Inc., d/b/a NorthWestern Energy (Nasdaq: NWE) (“ NWE Group ”), entered into a $225 million secured term loan credit agreement (the “ Term Loan ”) with Bank of America, N.A., as administrative agent (the \" Administrative Agent \"), and BOFA Securities, Inc., BMO Bank N.A., Keybank National Association, and U.S. Bank National Association, as joint lead arrangers and bookrunners.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1993004/000199300426000044/0001993004-26-000044-index.htm"}},{"accession":"0001437749-26-019065","ticker":"LIQT","company_name":"LIQTECH INTERNATIONAL INC","filed_at":"2026-06-01T21:17:04+00:00","headline":"LiqTech to convert $3M of $6M debt to equity, pay $3M cash in restructuring","event_type":"debt","sec_items":["1.01","3.02","9.01"],"materiality_score":0.65,"calibrated_materiality_score":0.65,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-26-019065","json":"https://secwatch.observer/filing/0001437749-26-019065.json","markdown":"https://secwatch.observer/filing/0001437749-26-019065.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1307579/000143774926019065/0001437749-26-019065-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1307579/000143774926019065/liqt20260601_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On May 26, 2026, LiqTech International, Inc. (the “Company”) entered into a Debt Cancellation Agreement (the “Debt Cancellation Agreement”) with affiliates of Bleichroeder L.P., 21 April Fund, L.P., and 21 April Fund, Ltd. (the “Note Holders”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1307579/000143774926019065/0001437749-26-019065-index.htm"}},{"accession":"0001193125-26-251718","ticker":"PFLT","company_name":"PennantPark Floating Rate Capital Ltd.","filed_at":"2026-06-01T21:09:48+00:00","headline":"PennantPark Floating Rate Capital issues $105M 7.375% Notes due 2031","event_type":"debt","sec_items":["1.01","9.01"],"materiality_score":0.5,"calibrated_materiality_score":0.5,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251718","json":"https://secwatch.observer/filing/0001193125-26-251718.json","markdown":"https://secwatch.observer/filing/0001193125-26-251718.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1504619/000119312526251718/0001193125-26-251718-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1504619/000119312526251718/d37162d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On June 1, 2026, PennantPark Floating Rate Capital Ltd. (the “Company”) and Equiniti Trust Company, LLC (the “Trustee”) entered into a Third Supplemental Indenture (the “Third Supplemental Indenture”) to the Indenture between the Company and the Trustee, dated March 23, 2021 (the “Base Indenture,” and together with the Third Supplemental Indenture, the “Indenture”).","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1504619/000119312526251718/0001193125-26-251718-index.htm"}},{"accession":"0001140361-26-023577","ticker":"TCPC","company_name":"BlackRock TCP Capital Corp.","filed_at":"2026-06-01T20:50:02+00:00","headline":"BlackRock TCP Capital closes $535.8M CLO securitization, repays existing debt facilities","event_type":"debt","sec_items":["1.01","1.02","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001140361-26-023577","json":"https://secwatch.observer/filing/0001140361-26-023577.json","markdown":"https://secwatch.observer/filing/0001140361-26-023577.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/ef20075169_8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On the Closing Date, TCPC II entered into a payoff letter (“ Payoff Letter ”) to terminate the Loan and Servicing Agreement dated as of August 4, 2020 (as amended, modified, supplemented, restated or replaced from time to time, the “ LSA ”) among TCPC II, as borrower, Special Value Continuation Partners LLC, as servicer, Morgan Stanley Asset Funding Inc., as administrative agent and Morgan Stanley Bank, N.A., City National Bank, as lenders and Wells Fargo Bank, National Association, as the collateral agent, the account bank and the collateral custodian.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1370755/000114036126023577/0001140361-26-023577-index.htm"}},{"accession":"0001967680-26-000034","ticker":"VLTO","company_name":"Veralto Corp","filed_at":"2026-06-01T20:48:48+00:00","headline":"Veralto issues $725M of 4.850% Senior Notes due 2032, net proceeds ~$718.8M","event_type":"debt","sec_items":["1.01","8.01","9.01"],"materiality_score":0.55,"calibrated_materiality_score":0.55,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001967680-26-000034","json":"https://secwatch.observer/filing/0001967680-26-000034.json","markdown":"https://secwatch.observer/filing/0001967680-26-000034.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1967680/000196768026000034/0001967680-26-000034-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1967680/000196768026000034/vlto-20260527.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On June 1, 2026, Veralto Corporation (the “Company”) issued $725,000,000 aggregate principal amount of 4.850% Senior Notes due 2032 (the “Notes”) in an underwritten offering (the “Offering”) pursuant to a registration statement on Form S-3ASR (File No. 333-282816) filed with the Securities and Exchange Commission (the “Commission”) on October 24, 2024 (the “Registration Statement”) and a preliminary prospectus supplement and prospectus supplement filed with the Commission related to the Offering. The Notes were issued under an indenture, dated as of June 1, 2026 (the “Base Indenture”) and the First Supplemental Indenture, dated as of June 1, 2026 (the “Supplemental Indenture” and, together with the Base Indenture, the “Indenture”), between the Company, as issuer, and Deutsche Bank Trust Company Americas, as trustee.","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1967680/000196768026000034/0001967680-26-000034-index.htm"}},{"accession":"0001193125-26-251551","ticker":"BFAM","company_name":"BRIGHT HORIZONS FAMILY SOLUTIONS INC.","filed_at":"2026-06-01T20:31:06+00:00","headline":"Bright Horizons secures $375M term loan, ups revolver to $1B with 2030 maturity","event_type":"debt","sec_items":["1.01","2.03","9.01"],"materiality_score":0.6,"calibrated_materiality_score":0.6,"match_reasons":["same fact type: material_agreement","same SEC item: 1.01, 9.01","same event type: debt","similar materiality"],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-251551","json":"https://secwatch.observer/filing/0001193125-26-251551.json","markdown":"https://secwatch.observer/filing/0001193125-26-251551.md","edgar_index":"https://www.sec.gov/Archives/edgar/data/1437578/000119312526251551/0001193125-26-251551-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1437578/000119312526251551/d139662d8k.htm"},"side_by_side_evidence":{"fact_type":"material_agreement","source_excerpt":"On April 10, 2026 (the “Effective Date”), Evofem Biosciences, Inc. (the “Company”), Adjuvant Global Health Technology Fund, L.P., and Adjuvant Global Health Technology Fund DE, L.P. (together, “Adjuvant”) entered into a fourth amendment (the “Fourth Amendment”) to the Securities Purchase Agreement dated as of October 14, 2020, as amended, pursuant to which Adjuvant purchased from the Company certain convertible promissory notes (the “Notes”).","source_evidence_url":"https://www.sec.gov/Archives/edgar/data/1618835/000149315226017082/0001493152-26-017082-index.htm","comparable_excerpt":"On June 1, 2026 (the “ Closing Date ”), Bright Horizons Family Solutions LLC (the “ Borrower ”), a wholly-owned indirect subsidiary of Bright Horizons Family Solutions Inc. (the “ Company ”), entered into the Fifth Amendment to Second Amended and Restated Credit Agreement","comparable_evidence_url":"https://www.sec.gov/Archives/edgar/data/1437578/000119312526251551/0001193125-26-251551-index.htm"}}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}